

~	L.D. 1601
2	DATE: 2/28/96 (Filing No. H-725)
4	URID: 2/20/90 (TITING NO. 11-725 /
6	HUMAN RESOURCES
8	
10	Reproduced and distributed under the direction of the Clerk of the House.
12	
14 16	STATE OF MAINE HOUSE OF REPRESENTATIVES 117TH LEGISLATURE SECOND REGULAR SESSION
18	COMMITTEE AMENDMENT " A " to H.P. 1169, L.D. 1601, Bill, "An
20	COMMITTEE AMENDMENT " []" to H.P. 1169, L.D. 1601, Bill, "An Act to Allow Physicians' Offices to Receive Discounts from Pharmaceutical Manufacturers"
22	
24	Amend the bill by striking out everything after the enacting clause and before the statement of fact and inserting in its place the following:
26	C. 1 22 MDCA 12004 85 .
28	'Sec.1. 32 MRSA 13804, sub-§5 is enacted to read:
40	5. Parenterally administered oncologic drug products
30	administered at medical office sites. This subchapter does not
32	apply to parenterally administered oncologic drug products administered at medical office sites.'
32	administered at medical office sites.
34	Further amend the bill by inserting at the end before the statement of fact the following:
36	
38	'FISCAL NOTE
40	This bill may decrease the number of civil suits filed in
	the court system. The Judicial Department may realize some minor
42	savings from reductions of workload and administrative costs
44	associated with the minimal number of cases that will no longer be filed. Reductions in the collection of filing fees may decrease General Fund revenue by minor amounts.'

il o

Page 1-LR2560(2)

,

COMMITTEE AMENDMENT

COMMITTEE AMENDMENT "A" to H.P. 1169, L.D. 1601

R. . .

2

4

STATEMENT OF FACT

	This amendment replaces the bill. It confines the exception
6	to the nondiscrimination in pharmaceutical pricing laws to
	parenterally administered oncologic drug products administered at
8	medical office sites. It also adds a fiscal note to the bill.

Page 2-LR2560(2)

COMMITTEE AMENDMENT